Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant afatinib followed by surgery in squamous cell carcinoma of the head and neck
2011-005820-17Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Metabolic response by FDG-PET/CT after 2 weeks of afatinib and prior to surgery. Started Apr 2012; status: completed.
02
Drugs
afatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2011-005820-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005820-17.